NATIONAL SURVEY OF PHYSICIANS CONCERNING PERCEPTIONS OF DRUG PRODUCT LABELING AND THE BRIEF SUMMARY

Forms and Documents

Document	Type	Status	Availability

No forms / supporting documents in this ICR. Check IC Document Collections.

IC Document Collections

IC ID	Collection	Type	Status	Form
109995	NATIONAL SURVEY OF PHYSICIANS CONCERNING PERCEPTIONS OF DRUG PRODUCT LABELING AND THE BRIEF SUMMARY		Migrated

ICR Details

OMB Control No: 0910-0290	ICR Reference No: 199304-0910-008
Status: Historical Active	Previous ICR Reference No:
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: NATIONAL SURVEY OF PHYSICIANS CONCERNING PERCEPTIONS OF DRUG PRODUCT LABELING AND THE BRIEF SUMMARY
Type of Information Collection: New collection (Request for a new OMB Control Number)	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 07/09/1993
	Date Received in OIRA: 04/12/1993
Terms of Clearance: We have approved this one-time information collection with the following conditions:1) As agreed to by FDA, question 1 of the survey will be revised to ask physicians whether someone else in their office retrieves/reviews label data for the physicians' use. 2) FDA will delete question 32, which asks respondents to agree or disagree with a a statement about comparative drug information. This information will be more useful if received as a voluntary response via question 14. 3) To the extent allowable by the sample, FDA should attempt to discer any systematic bias(es) that may arise, according to specialty (e.g. ob/gyn, internal medicine, pediatrics). Any such finding should be reported when discussing these data.

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	03/31/1994	03/31/1994
Responses	392	0	0
Time Burden (Hours)	118	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: TO PROVIDE INFORMATION FOR CDER LABELING PLANNING AND DEVELOPMENT, A NATIONAL SURVEY OF OFFICE-BASED PRACTICING PHYSICIANS WILL EXAMINE THE PERCEIVED USEFULNESS AND EFFECTIVENESS OF COMMUNICATION OF THE INFORMATION IN PRESCRIPTION DRUG LABELING AND THE SUMMARY OF LABELING INCLUDED IN PRESCRIPTION DRUG PRODUCT ADVERTISING.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:

---

Federal Register Notices & Comments

Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
NATIONAL SURVEY OF PHYSICIANS CONCERNING PERCEPTIONS OF DRUG PRODUCT LABELING AND THE BRIEF SUMMARY

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	392	0	0	392	0	0
Annual Time Burden (Hours)	118	0	0	118	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 04/12/1993

---